Eli Lilly and Company

LLY

$1,175.15

+2.46%

N/A+$28.25

Healthcare

Drug Manufacturers - General

NYSE

Active Trading

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the ...

Recent News of LLY

Foreign Policy Journal7/13/2026Somewhat-Bullish (0.296)

Novo Nordisk (NYSE: NVO), Realty Income (NYSE: O), And Enterprise Products Partners (NYSE: EPD) Offer High Yields As Second Half Of 2026 Gets Underway

This article highlights three high-yield stocks—Novo Nordisk (NVO), Realty Income (O), and Enterprise Products Partners (EPD)—for investors seeking reliable dividend income as the second half of 2026 begins. Novo Nordisk offers a 3.5% yield and is reclaiming market share in the GLP-1 drug segment, while Enterprise Products Partners provides a 5.9% yield with low commodity price exposure in the midstream energy sector. Realty Income, a REIT, delivers a consistent 5% monthly dividend with a long track record of increases, appealing to income-dependent investors.

TradingKey7/13/2026Somewhat-Bullish (0.195)

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled

Bristol-Myers Squibb Co (BMY) stock rose 3.07% on July 13, driven by positive clinical data in oncology and immunology, successful regulatory milestones, and effective cost-optimization efforts. The company's strategy to diversify revenue streams ahead of patent expirations and its strong financial management have increased investor confidence. Technical indicators also suggest a potential buy signal for BMY.

Bloomberg Law News7/13/2026Neutral (0.106)

Teva Revives Lilly Contract Suit Over Copy of Bone-Loss Drug

Teva Pharmaceuticals USA Inc. has successfully revived its breach-of-contract claim against Eli Lilly & Co. The Seventh Circuit Court of Appeals ruled that Teva presented a plausible argument that Lilly violated a settlement agreement from an earlier patent case regarding a generic version of Lilly’s osteoporosis drug Forteo, reversing a lower court's dismissal. The key issue was the district court's error in concluding the agreement necessarily expired with the Forteo patents at the pleading stage, as the settlement did not specify its expiration.

Reuters7/13/2026Somewhat-Bullish (0.305)

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The U.S. FDA has approved an at-home starter dose of Eisai and Biogen's Alzheimer's drug, Leqembi, allowing some patients to begin treatment with self-administered injections. This subcutaneous formulation, branded as Leqembi IQLIK, is expected to increase patient access and differentiate it from competitors. The approval was based on earlier trials of the intravenous version, showing effectiveness in early Alzheimer's disease.

TradingView7/13/2026Somewhat-Bullish (0.326)

XLV ETF Profile: Dividends, Returns (AMEX:XLV)

The article provides a detailed profile of the State Street Health Care Select Sector SPDR ETF (XLV), highlighting its investment strategy, holdings, and financial performance. It covers key statistics such as Assets Under Management (AUM), dividend yield, expense ratio, and details on its top holdings and regional exposure. The profile also addresses frequently asked questions regarding XLV's investments, dividends, and market performance.

Eli Lilly and Company

Recent News of LLY

Novo Nordisk (NYSE: NVO), Realty Income (NYSE: O), And Enterprise Products Partners (NYSE: EPD) Offer High Yields As Second Half Of 2026 Gets Underway

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled

Teva Revives Lilly Contract Suit Over Copy of Bone-Loss Drug

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

XLV ETF Profile: Dividends, Returns (AMEX:XLV)

Novo Nordisk (NYSE: NVO), Realty Income (NYSE: O), And Enterprise Products Partners (NYSE: EPD) Offer High Yields As Second Half Of 2026 Gets Underway

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled

Teva Revives Lilly Contract Suit Over Copy of Bone-Loss Drug

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

XLV ETF Profile: Dividends, Returns (AMEX:XLV)

Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades

LGT Fund Management Co Ltd. Makes New Investment in CVS Health Corporation $CVS

JPMorgan resumes Alkermes stock coverage with neutral rating

Lobbying Update: $80,000 of ELI LILLY AND COMPANY lobbying was just disclosed

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Which is the Better Choice for Healthcare Investors? IYH or BBH?

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Conning Inc. Has $33.85 Million Position in Amgen Inc. $AMGN

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY)

Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary

Tampa General Hospital sues major pharmaceutical company over drug pricing

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement

JNJ Stock Keeps Climbing. Should You Climb On?

Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

B. Riley Names Top Digital Health Stock to Buy

Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

Goldman Sachs Becomes OCIO for $70B From Verizon, Lockheed Martin

OZEM Archives

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Lockheed Martin, Verizon to Outsource DB and DC Investments to Goldman Sachs

Eli Lilly Rides Surging GLP-1 Demand Amid 11% U.S. Adoption

Verizon, Lockheed Martin to Outsource Pensions to Goldman Sachs Asset Management

Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Sam’s Club members get free Weight Watchers trial, up to 50% off

Strong LLY News Boosts Active Healthcare ETF GDOC

Adial Pharmaceuticals (Nasdaq:ADIL) - Stock Analysis

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Pfizer (PFE) On IBRANCE Approval And Dividend Move Has Valuation Back In Focus

Tampa General Hospital sues Eli Lilly over pulled 340B discounts

Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly

9 Health Care Stocks Whale Activity In Today’s Session

Citi Just Placed Micron on an Upside Catalyst Watch. What This Means for MU Stock.

Nurix Therapeutics earnings loom: Roche deal impact in focus By Investing.com

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of MGlu7 Modulation in Regulating Sleep and Wakefulness

Weight loss drug market to hit $130-150B by 203...

Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly